In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Gears Up To Launch US Advair Rival This Month

Executive Summary

Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.

You may also be interested in...



Mylan Launches US Advair Rival, Wixela Inhub, At A 70% Discount

Mylan has launched its Wixela Inhub rival to GSK’s Advair Diskus at a 70% discount to the brand price.

Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs

The latest drug development news and highlights from our US FDA Performance Tracker.

Mylan’s Nod For US Advair Rival Puts It A Year Ahead Of The Pack

The FDA’s approval for Mylan’s Wixela Inhub generic rival to GSK’s Advair Diskus is likely to give the company around a year’s head-start on other US generics being developed by Sandoz and Hikma.

Related Content

Topics

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel